Liberia

The company producing the new Ebola treatment for an FDA-approved test suddenly pulled out of Liberia, leaving researchers confused.

BUZZFEED                by Hayes Brown                                                                               Feb. 13, 2015

...An FDA-approved trial of the drug brincidofovir, meant to treat rather than prevent Ebola, had already begun in Liberia’s capital of Monrovia when Chimerix, the company that produced the drug, pulled out of the trial at the end of January. The clinical trial partners decided to end the trial on Feb. 3.

Peter Horby, who led the University of Oxford research team conducting the study, called the drug company’s decision “a bit abrupt.”

A woman is injected by a health care worker as she takes part in an Ebola virus vaccine trial in Monrovia Abbas Dulleh / Via AP

CENTER FOR INFECTIOUS DISEASE AND POLICY by  Lisa Schnirring                                                      Feb. 13, 2015

Novavax yesterday announced the launch of the first human trial of its recombinant Ebola vaccine, which will make it the fourth candidate vaccine to be tested in phase 1 trials.

Novavax's product is a glycoprotein recombinant nanoparticle vaccine adjuvanted with Matrix M (Ebola GP) to boost immune response. Conducted in Australia, the study will test the safety and immunogenicity of the vaccine, with and without the adjuvant, in 230 healthy adults ages 18 to 50. Subjects will be given two intramuscular injections 3 weeks apart....

Three other Ebola vaccines are in clinical trials. Phase 2 and 3 studies of the two vaccines that are furthest along in trials got under way in Liberia at the end of January. They include two vector virus vaccines, ChAd3, developed by the National Institutes of Health (NIH) and GlaxoSmithKline (GSK), and VSV-EBOV, developed by the Canadian government and licensed by NewLink Genetics and Merck.

A phase 1 trial of a prime-boost Ebola vaccine regimen from Johnson & Johnson launched in early January in the United Kingdom.

INTERNATIONAL BUSINESS TIMES  by Kathleen Caulderwood                                        Feb. 12., 2015

The worst Ebola outbreak in history is slowing down, but the affected countries are only beginning an economic struggle that could last for years.

Just as the U.S. recalled its troops from West Africa, the World Bank pledged millions of dollars in emergency aid to avoid a food crisis that could leave millions starving.      

“Agriculture is the lifeline of the economies of Guinea, Liberia and Sierra Leone,” Makhtar Diop, the World Bank's vice president for Africa, said in a Thursday statement.

“By speeding supplies of urgently needed seeds of major food crops to communities in West Africa, we are jump starting recovery in rural areas and preventing the looming specter of hunger in the countries hardest hit by Ebola.”

THE LANCET  by  Anna  Petherick  Volume 385, No. 9968, p591–592, 14 February 2015
The (West Africa) region has presented unforeseen challenges, and the three worst affected countries have put in place different response strategies. Anna Petherick reviews some of the lessons learned so far.

The early history of the ongoing Ebola outbreak in west Africa is a salutary statement about the lack of infectious disease surveillance capacity in one of the world's poorest regions....

Opportunities to contain the virus were lost soon after, largely because of a lack of trust between local communities and the officials and medical professionals trying to nip the epidemic in the bud.

Read complete story

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2960075-7/fulltext